Ones To Watch News
Refine Search
Biotechnology
Franco-American pairing Valneva and Pfizer have reported new data on their Lyme disease vaccine candidate, VLA15. 2 December 2022
Pharmaceutical
Well ahead of expectations, on December 1, the US Food and Drug Administration (FDA) approved Rezlidhia (olutasidenib) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. 2 December 2022
Biotechnology
Canada’s AbCellera and US biotech Rallybio Corporation have agreed a strategic alliance to discover, develop, and commercialize antibody-based therapeutics for rare diseases. 1 December 2022
Biotechnology
Switzerland-headquartered Roivant Sciences, a serial creator of new research-targeted start-ups, saw its share rise 7% to $5.74 by late-morning, after revealing a collaboration with US pharm giant Pfizer to establish a new “Vant” company. 1 December 2022
Biotechnology
Shares of Poland-based oncology specialist Ryvu Therapeutics closed up 17.7% at 51.19 zloty today, on news that the company had entered into a multi-target research collaboration with Germany’s BioNTech. 30 November 2022
Pharmaceutical
A regulatory approval could come within the next year for X4 Pharmaceuticals’ lead oral CXCR4 antagonist, mavorixafor. 30 November 2022
Biotechnology
Cambridge, USA-based biotech Ribon Therapeutics has entered into an agreement on the acquisition of its CD38 program with Germany’s family-owned pharma major Boehringer Ingelheim. 30 November 2022
Pharmaceutical
A Phase II miss for CinCor Pharma has sent the firm’s stock falling precipitously. Shares are now changing hands for around $14, 45% lower than last week. 29 November 2022
Biotechnology
Shares of Australian clinical-stage biotech Immutep closed up 4.3% at A$0.36 today, after it announced it has signed a second clinical trial and supply agreement with Germany’s Merck KGaA and US pharma giant Pfizer. 29 November 2022
Biosimilars
Dubai-based Bioventure, Egypt’s Minapharm Pharmaceuticals and German pharma MiGenTra have agreed to commercialize multiple biosimilars developed and manufactured by Alvotech, in 19 countries in Africa and the Middle East. 29 November 2022
Pharmaceutical
US central nervous system specialist Axsome Therapeutics saw its shares rocket more than 32% to $74.84 yesterday, after it announced positive late-stage clinical results with its drug candidate in Alzheimer’s disease agitation. 29 November 2022
Biotechnology
Shares in Arcus Biosciences were more than 7% higher at lunchtime Monday. 28 November 2022
Biotechnology
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA), submitted by rare diseases specialist Sarepta Therapeutics, seeking accelerated approval of SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD). 28 November 2022
Pharmaceutical
French pharma company MedinCell has signed a new 40 million-euro ($41.6 million) loan agreement with the European Investment Bank (EIB), backed by the Investment Plan for Europe. 25 November 2022
Biotechnology
Privately-held Italian drugmaker Chiesi announced that its new center of excellence for the development and production of biologic drugs, currently under construction, will be built in Parma in the area of the production plant where the company is headquartered. 24 November 2022
Biotechnology
California, USA-based BioMarin Pharmaceutical saw its shares leap 10.7% to $98.49 yesterday, after it announced that the US Food and Drug Administration (FDA) review of the Biologics License Application (BLA) of Roctavian (valoctocogene roxaparvovec AAV gene therapy) for adults with severe hemophilia A would not, after all, be submitted for review by the agency’s advisory panel. 24 November 2022
Biotechnology
US biotech Arvinas closed 16% lower after Monday’s trading. 23 November 2022
Biotechnology
Munich, Germany-based clinical-stage biotech CatalYm said today it has successfully closed a 50 million-euro ($49 million) Series C financing round. 22 November 2022
Biotechnology
Privately-held Swiss ophthalmology company Oculis has released positive results of the licaminlimab active-controlled, multicenter, randomized, parallel-group Phase II clinical trial assessing the effect of topical licaminlimab (OCS-02) on anterior chamber (AC) cell grade in patients with acute anterior uveitis (AAU). 22 November 2022
Biotechnology
Franco-American biopharma Erytech Pharma revealed Monday that the company will no longer be developing its lead candidate Graspa (eryaspase), an l-asparaginase encapsulated inside donor-derived red blood cells (RBCs). 22 November 2022
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze